Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rallybio (RLYB) Current Deferred Revenue (2024 - 2025)

Rallybio's Current Deferred Revenue history spans 2 years, with the latest figure at $212000.0 for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 75.0% to $212000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $212000.0, a 75.0% decrease, with the full-year FY2025 number at $212000.0, down 75.0% from a year prior.
  • Current Deferred Revenue hit $212000.0 in Q4 2025 for Rallybio, down from $424000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for RLYB hit a ceiling of $1.2 million in Q2 2024 and a floor of $212000.0 in Q4 2025.